These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 33801154)

  • 1. Addressing Pediatric HIV Pretreatment Drug Resistance and Virologic Failure in Sub-Saharan Africa: A Cost-Effectiveness Analysis of Diagnostic-Based Strategies in Children ≥3 Years Old.
    Siriruchatanon M; Liu S; Carlucci JG; Enns EA; Duarte HA
    Diagnostics (Basel); 2021 Mar; 11(3):. PubMed ID: 33801154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of pre-ART HIV drug resistance testing in Kenyan women.
    Duarte HA; Babigumira JB; Enns EA; Stauffer DC; Shafer RW; Beck IA; Garrison LP; Chung MH; Frenkel LM; Bendavid E
    EClinicalMedicine; 2020 May; 22():100355. PubMed ID: 32490370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: A modeling study.
    Hauser A; Kusejko K; Johnson LF; Günthard HF; Riou J; Wandeler G; Egger M; Kouyos RD
    PLoS Med; 2020 Dec; 17(12):e1003397. PubMed ID: 33315863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of HIV drug resistance testing to inform switching to second line antiretroviral therapy in low income settings.
    Phillips A; Cambiano V; Nakagawa F; Mabugu T; Miners A; Ford D; Pillay D; De Luca A; Lundgren J; Revill P
    PLoS One; 2014; 9(10):e109148. PubMed ID: 25290340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High levels of pre-treatment HIV drug resistance and treatment failure in Nigerian children.
    Boerma RS; Boender TS; Sigaloff KC; Rinke de Wit TF; van Hensbroek MB; Ndembi N; Adeyemo T; Temiye EO; Osibogun A; Ondoa P; Calis JC; Akanmu AS
    J Int AIDS Soc; 2016; 19(1):21140. PubMed ID: 27836020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States.
    Girouard MP; Sax PE; Parker RA; Taiwo B; Freedberg KA; Gulick RM; Weinstein MC; Paltiel AD; Walensky RP
    Clin Infect Dis; 2016 Mar; 62(6):784-91. PubMed ID: 26658053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal monitoring strategies for guiding when to switch first-line antiretroviral therapy regimens for treatment failure in adults and adolescents living with HIV in low-resource settings.
    Chang LW; Harris J; Humphreys E
    Cochrane Database Syst Rev; 2010 Apr; (4):CD008494. PubMed ID: 20393969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring and switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: collaborative analysis.
    Haas AD; Keiser O; Balestre E; Brown S; Bissagnene E; Chimbetete C; Dabis F; Davies MA; Hoffmann CJ; Oyaro P; Parkes-Ratanshi R; Reynolds SJ; Sikazwe I; Wools-Kaloustian K; Zannou DM; Wandeler G; Egger M;
    Lancet HIV; 2015 Jul; 2(7):e271-8. PubMed ID: 26423252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines.
    Phillips AN; Bansi-Matharu L; Venter F; Havlir D; Pozniak A; Kuritzkes DR; Wensing A; Lundgren JD; Pillay D; Mellors J; Cambiano V; Jahn A; Apollo T; Mugurungi O; Ripin D; Da Silva J; Raizes E; Ford N; Siberry GK; Gupta RK; Barnabas R; Revill P; Cohn J; Calmy A; Bertagnolio S
    Lancet HIV; 2020 Mar; 7(3):e193-e200. PubMed ID: 32035041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of switching to second-line antiretroviral therapy and associated factors in children with HIV: an international cohort collaboration.
    Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Global Cohort Collaboration
    Lancet HIV; 2019 Feb; 6(2):e105-e115. PubMed ID: 30723008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of laboratory monitoring for management of HIV treatment in sub-Saharan Africa: a model-based analysis.
    Hamers RL; Sawyer AW; Tuohy M; Stevens WS; Rinke de Wit TF; Hill AM;
    AIDS; 2012 Aug; 26(13):1663-72. PubMed ID: 22695297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pretreatment HIV drug resistance increases regimen switches in sub-Saharan Africa.
    Boender TS; Hoenderboom BM; Sigaloff KC; Hamers RL; Wellington M; Shamu T; Siwale M; Labib Maksimos EE; Nankya I; Kityo CM; Adeyemo TA; Akanmu AS; Mandaliya K; Botes ME; Ondoa P; Rinke de Wit TF
    Clin Infect Dis; 2015 Dec; 61(11):1749-58. PubMed ID: 26240203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing.
    Moore CL; Turkova A; Mujuru H; Kekitiinwa A; Lugemwa A; Kityo CM; Barlow-Mosha LN; Cressey TR; Violari A; Variava E; Cotton MF; Archary M; Compagnucci A; Puthanakit T; Behuhuma O; Saϊdi Y; Hakim J; Amuge P; Atwine L; Musiime V; Burger DM; Shakeshaft C; Giaquinto C; Rojo P; Gibb DM; Ford D;
    BMC Infect Dis; 2021 Jan; 21(1):5. PubMed ID: 33446115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the management of pretreatment HIV drug resistance by oligonucleotide ligation assay: a randomised controlled trial.
    Chung MH; McGrath CJ; Beck IA; Levine M; Milne RS; So I; Andersen N; Dross S; Coombs RW; Chohan B; Yatich N; Kiptinness C; Sakr SR; Kiarie JN; Frenkel LM
    Lancet HIV; 2020 Feb; 7(2):e104-e112. PubMed ID: 31818716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan Africa.
    Boender TS; Kityo CM; Boerma RS; Hamers RL; Ondoa P; Wellington M; Siwale M; Nankya I; Kaudha E; Akanmu AS; Botes ME; Steegen K; Calis JC; Rinke de Wit TF; Sigaloff KC
    J Antimicrob Chemother; 2016 Oct; 71(10):2918-27. PubMed ID: 27342546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The REVAMP trial to evaluate HIV resistance testing in sub-Saharan Africa: a case study in clinical trial design in resource limited settings to optimize effectiveness and cost effectiveness estimates.
    Siedner MJ; Bwana MB; Moosa MS; Paul M; Pillay S; McCluskey S; Aturinda I; Ard K; Muyindike W; Moodley P; Brijkumar J; Rautenberg T; George G; Johnson B; Gandhi RT; Sunpath H; Marconi VC
    HIV Clin Trials; 2017 Jul; 18(4):149-155. PubMed ID: 28720039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Challenges of scale-up to dolutegravir-based regimens in sub-Saharan Africa.
    Salou M; Butel C; Comlan AS; Konou AA; Tegueni K; Ehlan A; Lack F; Dossim S; Ayouba A; Delaporte E; Dagnra AY; Peeters M
    AIDS; 2020 Apr; 34(5):783-787. PubMed ID: 31895149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alarming increase in pretreatment HIV drug resistance in children living in sub-Saharan Africa: a systematic review and meta-analysis.
    Boerma RS; Sigaloff KC; Akanmu AS; Inzaule S; Boele van Hensbroek M; Rinke de Wit TF; Calis JC
    J Antimicrob Chemother; 2017 Feb; 72(2):365-371. PubMed ID: 27999070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Should We Be Testing for Baseline Integrase Resistance in Patients Newly Diagnosed With Human Immunodeficiency Virus?
    Koullias Y; Sax PE; Fields NF; Walensky RP; Hyle EP
    Clin Infect Dis; 2017 Oct; 65(8):1274-1281. PubMed ID: 28605418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Impact and Cost-effectiveness of Genotype Testing at Human Immunodeficiency Virus Diagnosis in the United States.
    Hyle EP; Scott JA; Sax PE; Millham LRI; Dugdale CM; Weinstein MC; Freedberg KA; Walensky RP
    Clin Infect Dis; 2020 Mar; 70(7):1353-1363. PubMed ID: 31055599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.